1. Abstract submitters should ensure that the version sent is the final one; changes will not be permitted once the deadline has passed.
2. Institution information should be provided for all authors. Please include institution, city, state/province and country but exclude department, division, laboratory, etc.
3. Categories: please select the category from the list displayed in the drop down menu which will be as follows:
Women and Pregnancy
4. Abstracts should be structured in 4 sections as follows:
Purpose: Should indicate the objectives of the work being presented.
Method: Should describe study material or subjects (e.g. number and type of patients), intervention and evaluation procedures.
Results: Should summarize the main findings. Wherever possible, give numerical values, including means with SD or SEM, and statistical significance or confidence intervals.
Conclusion: Should state briefly the conclusions reached in the work.
5. Figures, tables and other illustrations cannot be included.
6. If the work was supported by funds provided by a commercial organization this should be stated in a short acknowledgment at the end of the abstract. Other sources of funding may be acknowledged in the same way.
7. Multiple submissions of abstracts describing different components of the same study is not appropriate. All findings generated from the same study should be included in a single abstract.
8. Abstracts containing single case reports will not usually be accepted, unless the report is of outstanding scientific or clinical interest because of the uniqueness of the findings or the sophistication of the investigations.
9. Abstracts containing data considered to be insufficiently informative will not be accepted.
10. Authors should use a concise title that indicates the content of the abstract. Abbreviations should be avoided in the title.
11. For intervention studies (for example, therapeutic trials), type of design (prospective or retrospective, controlled or uncontrolled, randomized or observational, open vs. single-blind vs. double-blind), dosages, assessment methods and duration of follow-up should be specified.
12. Non-proprietary names of drugs must be used throughout. If results are considered to be specific for a given proprietary product (for example, bio-equivalence studies), the non-proprietary name must still be used, followed by the proprietary name and the name of the manufacturers in brackets.
13. Abbreviations should be used sparingly. For words that are abbreviated, use the whole term the first time, followed by the standard abbreviation in parenthesis. For anti-epileptic drugs, standard abbreviations are those published in Epilepsia 1993; 34:1151.
14. References should be used sparingly. They should be included within the text in brackets. For journals, mention first author "et al" followed by the name of the journal as abbreviated in the Index Medicus, year, volume number and inclusive pages (i.e. Hardus P et al. Epilepsia 2001;42:262-267.). For book chapters, give first author "et al", editor, title, publisher, city of publication, year and inclusive pages (i.e. Levy RH et al. In: Levy RH et al, Antiepileptic Drugs. Lippincott-Raven, 1996;13-30.).
15. Submission of an abstract automatically implies acknowledgment that the work described was conducted in accordance with current ethical standards and regulations in biomedical research. Failure to adhere to these standards will result in rejection of the abstract.